Organism: Homo sapiens
Gene: 38543_at
Selected probe(set): 208212_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38543_at (208212_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):5.042506
Number of Samples:3 / 20

Experimental	lung adenocarcinoma study 5 (EML4-ALK)
	Primary tumor sample from patients with stage I adenocarcinoma carrying the EML4-ALK-fusion.
Control	adjacent lung tissue
	Adjacent and histologically normal, non-tumorous lung tissue samples from patients with lung adenocarcinoma.

Relative Expression (log2-ratio):-4.9959774
Number of Samples:24 / 8

Experimental	lung adenocarcinoma study 6 (EGFR mut)
	Primary tumor sample from patients with stage II adenocarcinoma carrying an EGFR mutation.
Control	lung adenocarcinoma study 6 (EML4-ALK)
	Primary tumor sample from patients with stage II adenocarcinoma carrying the EML4-ALK-fusion.

Relative Expression (log2-ratio):-4.991205
Number of Samples:103 / 3

Experimental	lung adenocarcinoma study 5 (EGFR mut)
	Primary tumor sample from patients with stage I adenocarcinoma carrying an EGFR mutation.
Control	lung adenocarcinoma study 5 (EML4-ALK)
	Primary tumor sample from patients with stage I adenocarcinoma carrying the EML4-ALK-fusion.

Relative Expression (log2-ratio):4.9298353
Number of Samples:8 / 20

Experimental	lung adenocarcinoma study 6 (EML4-ALK)
	Primary tumor sample from patients with stage II adenocarcinoma carrying the EML4-ALK-fusion.
Control	adjacent lung tissue
	Adjacent and histologically normal, non-tumorous lung tissue samples from patients with lung adenocarcinoma.

Relative Expression (log2-ratio):4.9138927
Number of Samples:8 / 20

Experimental	lung adenocarcinoma study 6 (EML4-ALK)
	Primary tumor sample from patients with stage II adenocarcinoma carrying the EML4-ALK-fusion.
Control	lung adenocarcinoma study 6 (EGFR/K-RAS/ALK -)
	Primary tumor sample from patients with triple-negative stage II adenocarcinoma of the lung. The patients were not carrying any mutation in the EGFR, K- RAS or ALK gene.

Relative Expression (log2-ratio):4.9070683
Number of Samples:3 / 48

Experimental	lung adenocarcinoma study 5 (EML4-ALK)
	Primary tumor sample from patients with stage I adenocarcinoma carrying the EML4-ALK-fusion.
Control	lung adenocarcinoma study 5 (EGFR/K-RAS/ALK -)
	Primary tumor sample from patients with triple-negative stage I adenocarcinoma of the lung. The patients were not carrying any mutation in the EGFR, K- RAS or ALK gene.

Relative Expression (log2-ratio):-4.8807516
Number of Samples:14 / 3

Experimental	lung adenocarcinoma study 5 (K-RAS mut)
	Primary tumor sample from patients with stage I adenocarcinoma carrying a K-RAS mutation.
Control	lung adenocarcinoma study 5 (EML4-ALK)
	Primary tumor sample from patients with stage I adenocarcinoma carrying the EML4-ALK-fusion.

Relative Expression (log2-ratio):4.8320255
Number of Samples:2 / 64

Experimental	basal cell carcinoma study 2
	Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).
Control	normal skin tissue
	Normal skin samples from healthy donors.

Relative Expression (log2-ratio):-4.4821672
Number of Samples:6 / 8

Experimental	lung adenocarcinoma study 6 (K-RAS mut)
	Primary tumor sample from patients with stage II adenocarcinoma carrying a K-RAS mutation.
Control	lung adenocarcinoma study 6 (EML4-ALK)
	Primary tumor sample from patients with stage II adenocarcinoma carrying the EML4-ALK-fusion.

Relative Expression (log2-ratio):-3.6711426
Number of Samples:5 / 7

Experimental	E. coli study 2
	Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli.
Control	unstimulated, normal monocyte-derived macrophage sample
	Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated.